GlassScriptPhysician profile
Jason M Leider
NPI 1417035791
$694,052.63
in general payments reported to CMS, 2019-2025
8 companies · $101K in 2025
The $101K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181K · 2020: $46K · 2021: $57K · 2022: $80K · 2023: $111K · 2024: $118K · 2025: $101K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $270K · Travel and Lodging: $30K · Consulting Fee: $19K · Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $270,017.50 |
| Travel and Lodging | $29,718.76 |
| Consulting Fee | $19,132.50 |
| Food and Beverage | $10,372.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $223,429.06 | 2019-2025 | Biktarvy, Descovy, Yeztugo |
| Viiv Healthcare Company | $197,098.78 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Janssen Products, LP | $122,980.23 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $74,240.36 | 2019-2023 | Pifeltro, Delstrigo |
| Theratechnologies INC. | $74,197.41 | 2019-2024 | Trogarzo, Egrifta |
| Janssen Scientific Affairs, LLC | $1,738.97 | 2019-2023 | Symtuza |
| Janssen Biotech, INC. | $339.34 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Leider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.